Savings Associated With "Skinny Label" Biosimilars

JAMA Intern Med. 2023 Jan 1;183(1):84. doi: 10.1001/jamainternmed.2022.5418.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Biosimilar Pharmaceuticals*
  • Cost Savings
  • Drug Approval
  • Humans
  • Income

Substances

  • Biosimilar Pharmaceuticals